Pharmaceuticals & Therapeutics

A new strategic alliance brings European cGMP-grade vitamin APIs to the U.S., promising to enhance quality and supply reliability for compounding pharmacies.

From nano-surfactants to pharmaceuticals, SureNano Science is betting its future on a novel obesity drug. Can this microcap survive the big leagues?

Pharma and COVID-response leader John Young joins UCSF's QBI to translate its cutting-edge protein science into transformative therapies and partnerships.

Response Pharmaceuticals unveils promising data on RDX-002, a first-in-class drug aimed at preventing a severe side effect of essential mental health drugs.

Arvinas secures a historic first FDA approval for a PROTAC drug and inks a deal to fuel a deep pipeline targeting cancer and neurodegenerative diseases.

A new report reveals that equipment fires, regulatory hurdles, and subtle operational flaws are emerging as major threats to the clean energy transition.

A new specialty clinic in Philadelphia tackles a nationwide shortage of pet dentists, offering advanced, team-based oral care for common animal ailments.

With demand for blood and plasma soaring, Canadian Blood Services is betting on national pride to solve a critical shortage. But can a new campaign work?

Biotech firm AstronauTx appoints a new CMO and VP, signaling a pivotal move to clinical trials for its novel Alzheimer's therapy targeting sleep architecture.

Javier Vasquez of Miguel's Restaurants joins the LLUCH Foundation board, blending a 50-year family legacy with a new era of strategic philanthropy.

With two pivotal trial readouts looming and cash projected to last only into Q4, Tvardi Therapeutics faces a make-or-break year for its STAT3 inhibitors.

As Talphera preps its Q1 update, all eyes are on its breakthrough drug Niyad® and the mounting costs of bringing a potential game-changer to market.

After 40 years, capsule giant CapsCanada becomes Lyfe Group, a strategic move to unify its brand, leverage new investments, and lead the drug delivery market.

Vancouver's ME Therapeutics will unveil its in-vivo immune reprogramming technology, a potential cancer treatment game-changer, to global investors.

A massive $250M investment could replace a 40-pill daily burden with a single tablet for patients with pancreatic insufficiency, disrupting a market in crisis.

A landmark European trial for a new genomic test has passed 50% recruitment, promising to tailor breast cancer therapy and improve patient quality of life.

Fueled by a $100M R&D investment, Chinese beauty giant Yatsen is leading a market shift from price wars to scientific innovation, winning global consumers.

The diagnostics firm's stellar quarter is fueled by surging test volumes and a new non-invasive prenatal test poised to disrupt high-risk screening.

As Walmart Canada launches its annual campaign for kids' health, a look at how decades of donations address critical gaps in a strained medical system.

Diathrive Health and AliveCor's KardiaComplete partner to offer an integrated solution for diabetes and heart disease, combating fragmented care and rising costs.